The Survival Benefit of Neo-adjuvant Therapy Among Women Undergoing Breast Reconstruction Surgery: A Real World Study

Abstract

As a crucial therapeutic regimen, the popularity of breast reconstruction surgery (BRS) has partly been driven by the rise in the utilization of neo-adjuvant therapy (Neo-AT). However, few studies have specifically examined the survival outcome for patients underwent BRS after Neo-AT. This study aimed to investigate and elucidate the survival benefit of neo-adjuvant therapy (Neo-AT) and adjuvant therapy (AT) among the women who underwent BRS. A total of 18919 patients were obtained from the Surveillance, Epidemiology, and End Results (SEER) database between 2007 and 2020. Kaplan-Meier, Cox regression model, and propensity score matching (PSM) analyses were employed to identify the predictors associated with the survival. A nomogram was developed using the variables selected by multivariable Cox analysis to predict short and long-term probabilities of BCSS. In this study, the administration of Neo-AT was founded to be associated with a worse prognosis in comparison with AT. This model is anticipated to offer precise and personalized prediction in BCSS, aiding in treatment decision-making.